US Market

I-MAB (IMAB) Stock Price & Analysis


IMAB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.73 - $12.76
Previous Close$3.14
Average Volume (3M)344.99K
Market Cap
Enterprise Value-$3.08B
Total Cash (Recent Filing)¥3.34B
Total Debt (Recent Filing)¥10.87M
Price to Earnings (P/E)-0.7
Aug 29, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.46
Shares Outstanding83,440,000
10 Day Avg. Volume196,878
30 Day Avg. Volume344,992
Standard Deviation0.23
Financial Highlights & Ratios
Price to Book (P/B)0.10
Price to Sales (P/S)-1.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside696.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was I-MAB’s price range in the past 12 months?
I-MAB lowest stock price was $2.73 and its highest was $12.76 in the past 12 months.
    What is I-MAB’s market cap?
    Currently, no data Available
    When is I-MAB’s upcoming earnings report date?
    I-MAB’s upcoming earnings report date is Aug 29, 2023 which is in 80 days.
      How were I-MAB’s earnings last quarter?
      I-MAB released its earnings results on Mar 31, 2023. The company reported -$0.14 earnings per share for the quarter, the consensus estimate of -$0.14 by $0.
        Is I-MAB overvalued?
        According to Wall Street analysts I-MAB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does I-MAB pay dividends?
          I-MAB does not currently pay dividends.
          What is I-MAB’s EPS estimate?
          I-MAB’s EPS estimate is -$0.34.
            How many shares outstanding does I-MAB have?
            I-MAB has 83,439,740 shares outstanding.
              What happened to I-MAB’s price movement after its last earnings report?
              I-MAB reported an EPS of -$0.14 in its last earnings report, expectations of -$0.14. Following the earnings report the stock price went down -1.705%.
                Which hedge fund is a major shareholder of I-MAB?
                Among the largest hedge funds holding I-MAB’s share is Bridgewater Associates, LP. It holds I-MAB’s shares valued at 524K.


                  I-MAB Stock Smart Score

                  The I-MAB stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.


                  Top 5 ETFs holding IMAB

                  Market Value
                  Smart Score
                  iShares NASDAQ US Biotechnology UCITS ETF
                  Invesco Nasdaq Biotechnology ETF
                  Up to five ETFs with an Outperform Smart Score that hold IMAB. The ETFs are listed according to market value of IMAB within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  RAPT Therapeutics
                  Bellicum Pharmaceuticals
                  Takeda Pharmaceutical Company
                  Rocket Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis